Read Dr. Austin’s message about a request for feedback to enhance the CTSA Program, learn about a new funding opportunity to join the Biomedical Data Translator program and follow a former postbac fellow’s journey to becoming a translational scientist.
NIH has awarded approximately $38 million in grants to 20 teams and a data management center to study rare diseases. Research groups will collaborate to learn more about the causes and progression of rare diseases and develop new treatment approaches.
NIH has awarded $89 million for 24 research projects that aim to develop high-quality tools for performing safe and effective genome editing in humans. Advances in the field could lead to new treatments for both common and rare genetic diseases.
NCATS is offering a funding opportunity for institutions and individuals to participate in the next phase of its Biomedical Data Translator program. The aim is to accelerate biomedical translation by developing a “data translator” research resource.
NCATS supports several training and career development programs that not only inspire students to become scientists but also help grow the translational science workforce. Read about one student’s journey to becoming a translational scientist.
Researchers can better study the effect of compounds on cells with an NCATS resource that incorporates all known pathways in human cells into one database. BioPlanet lets users browse, retrieve and analyze the pathways and explore pathway connections.
NCATS-supported researchers have developed an automated machine-learning approach to diagnose genetic diseases in seriously ill children. This new approach could allow faster diagnosis, initiation of treatment, and, ultimately, better outcomes.
A research framework that enables recruiting of hospitalized patients for a wide range of studies helps identify optimal care approaches during and after hospital stays. Undergraduate students learn about clinical research and are integral to recruitment.
NCATS-supported researchers used machine-learning to develop an innovative device that detects dangerous internal bleeding and monitors a patient’s response to blood loss. The monitor helps medical staff quickly identify appropriate treatment.
September 26, 2019: We Want Your Input on the CTSA Program to Ensure Our Collective Success!
Christopher P. Austin, M.D., asks stakeholders for input to strengthen the Clinical and Translational Science Awards (CTSA) Program. The deadline to respond to the Request for Information is October 25.